Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

Business Wire October 31, 2022

Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic

Business Wire October 27, 2022

Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

Business Wire October 20, 2022

Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors

Business Wire October 13, 2022

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

Business Wire October 4, 2022

Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

Business Wire September 12, 2022

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire September 1, 2022

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

Business Wire August 8, 2022

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease Psychosis

Business Wire August 4, 2022

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

Business Wire July 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

PR Newswire July 21, 2022

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

Business Wire July 18, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

PR Newswire July 13, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

Newsfile July 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD

PR Newswire July 5, 2022

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis

Business Wire June 17, 2022

Acadia Pharmaceuticals Stock Trading Halted Today

Business Wire June 17, 2022

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

Business Wire May 4, 2022

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire May 3, 2022

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis Scheduled for June 17, 2022

Business Wire May 2, 2022